Learn More About Our Innovative Biotechnology
Watch as Dr. Deisher presents AVM0703 in the Novel and Outstanding Discoveries track at the European Scientific Working Group on Influenza (ESWI).
Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients dosed with AVM0703
April 7, 2021 – Seattle, AVM Biotechnology announced today that the first cohort has been fully enrolled in their clinical study (NCT04329728 “The WWRD Study”).
AVM Biotechnology – The Platform Therapy for Immune Modulation
Learn more about AVM Biotechnology.
Pharma’s Almanac Features AVM0703
Combating cancer and other diseases with supercharged natural killer T-cells, mobilized by a novel formulation of Dexamethasone – Theresa Deisher, Ph.D., CEO and Founder of AVM Biotechnology, spoke with Pharma's Almanac Managing Editor Emilie Branch.
AVM Biotechnology CEO/CSO Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track
Seattle, December 2, 2020 – AVM Biotechnology, a company developing a proprietary and innovative form of dexamethasone, today announced that CEO/CSO, Dr. Theresa Deisher has been selected to present during the Novel and Outstanding Discoveries Track at the European Scientific Working Group on Influenza (ESWI).
What is AVM0703? Find Out!
Learn more about AVM0703 as treatment for Acute Respiratory Distress Syndrome (ARDS).
President Receives Dexamethasone Treatment
Seattle, October 7, 2020 – As part of the standard of care treatment protocol, President Trump received dexamethasone for his COVID-19 disease, highlighting the value of dexamethasone. Dexamethasone has been widely used since its initial approval in 1958 in treating acute disease.
AVM Receives FDA Permission for Clinical Trials in COVID-19/ARDS
Seattle, September 16,2020 – AVM Biotechnology has received FDA permission to proceed with clinical trials to evaluate its proprietary drug AVM0703 in the treatment of Acute Respiratory Distress Syndrome (ARDS) mediated by COVID-19 or Influenza patients.
AVM Expands Executive Team, Appoints Janet R. Rea COO
Seattle, July 8, 2020 – AVM Biotechnology, a Seattle-based up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma, and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer.
Amplifying Scientific Innovation Podcast
Dr. Deisher on Amplifying Science speaking with Dr. Sofia Ononye-Onyia regarding scientific innovation including AVM0703.
AVM’s Dexamethasone Formulation Has Potential For Greater Impact Than Oxford’s
Seattle, June 17, 2020 – Oxford University announced yesterday that dexamethasone could reduce deaths in the sickest COVID-19 patients.
Oxford/AVM’s potential COVID-19 Treatment Featured on KOMO News
KOMO News reports on Dexamethasone and AVM0703 as a potential treatment for COVID-19.
AVM Awarded SBIR Grant From National Cancer Institute
Seattle, June 11, 2020 – AVM Biotechnology has been awarded a National Cancer Institute Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) to study the use of their lead molecule AVM0703 as a preconditioning agent to allow safe and efficient delivery of therapeutic immune cells for cancer treatment.
FDA Approves AVM0703 Clinical Trials in R/R Non-Hodgkins Lymphoma
Seattle, April 20, 2020 – AVM Biotechnology announces clinical trial approval for AVM0703, an exciting new drug to treat terminal no-option Non-Hodgkin’s Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia.
Cavendish Global 2020
Dr. Deisher presents AVM0703 as a potential first choice for no option cancer and autoimmune disease.
AVM0703, a New Treatment Option for Lymphoma Patients
AVM0703 is a new treatment option for lymphoma patients that can eliminate or reduce the dose of standard chemotherapy in the overall treatment plan.